SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Feb 13, 2018
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Feb. 13, 2018 · CIK: 0001503802 · Accession: 0001193125-18-041454
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222726
Letter
KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE, SECOND FLOOR
NEWTON, MA 02459
February 13, 2018
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Karyopharm Therapeutics Inc.
Registration Statement on Form S-3
File No. 333-222726
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-222726), so that it may become effective at 4:00 p.m. Eastern time on February 15, 2018, or as soon thereafter as practicable.
Very truly yours,
Karyopharm Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP KARYOPHARM THERAPEUTICS INC. 85 WELLS AVENUE, SECOND FLOOR NEWTON, MA 02459 February 13, 2018 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-3 File No. 333-222726 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Karyopharm Therapeutics Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-222726), so that it may become effective at 4:00 p.m. Eastern time on February 15, 2018, or as soon thereafter as practicable. Very truly yours, Karyopharm Therapeutics Inc. By: /s/ Christopher B. Primiano Name: Christopher B. Primiano Title: Executive Vice President, Chief Business Officer, General Counsel and Secretary